Alexander Federation
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$7.3MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $7.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jan 16, 2025 | NIH | SBIR Phase II Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | $822K | TALUS BIOSCIENCE, INC. |
| Jun 12, 2024 | NIH | SBIR Phase II Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | $1.0M | TALUS BIOSCIENCE, INC. |
| Feb 28, 2024 | NIH | SBIR Phase II Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | $822K | TALUS BIOSCIENCE, INC. |
| Aug 14, 2023 | NIH | SBIR Phase I Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | $307K | TALUS BIOSCIENCE, INC. |
| Aug 14, 2023 | NIH | SBIR Phase II Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | $307K | TALUS BIOSCIENCE, INC. |
| Jul 1, 2023 | NIH | SBIR Phase II Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | $1.0M | TALUS BIOSCIENCE, INC. |
| Jun 16, 2023 | NIH | SBIR Phase II Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | $1.0M | TALUS BIOSCIENCE, INC. |
| Apr 1, 2022 | NIH | STTR Phase I Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | $455K | TALUS BIOSCIENCE, INC. with UNIVERSITY OF WASHINGTON |
| Apr 1, 2022 | NIH | SBIR Phase I Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding | $334K | TALUS BIOSCIENCE, INC. |
| Mar 24, 2022 | NIH | STTR Phase II Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | $455K | TALUS BIOSCIENCE, INC. |
| Mar 15, 2022 | NIH | SBIR Phase I Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding | $334K | TALUS BIOSCIENCE, INC. |
| Jun 1, 2021 | NSF | SBIR Phase I SBIR Phase I: Simultaneous In situ Pharmacological Profiling of Gene Regulatory Proteins (GRPs) for Cancer Therapy | $256K | TALUS BIOSCIENCE, INC. |
| Apr 21, 2021 | NSF | SBIR Phase I SBIR Phase I: Simultaneous In situ Pharmacological Profiling of Gene Regulatory Proteins (GRPs) for Cancer Therapy | $256K | TALUS BIOSCIENCE, INC. |
Peer ranks
Federal funding#131
Awards as PI#72
Patents#273
Companies
- TALUS BIOSCIENCE, INC.Linked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.